Patent US5225337A successfully refreshed from Google Patents.
US5225337A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Ribozyme compositions and methods for use
Assignee: NEW YORK STATE SCIENCE & TECHNOLOGY FOUNDATION
•
Filing: 1989-09-25
•
Granted: 1993-07-06
•
Expires: 2009-09-25
Abstract
Abstract Ribozymes, sequences cleaving RNA, derived from sequences present in the hepatitis delta virus, have been engineered for greater specificity without increasing size. The specific ribozyme sequences are useful as reagents for cleaving RNA for experimental studies as well as antiviral therapies. Examples demonstrating the targeting of these sequences against HIV and Crohn's disease are described in detail. The sequences are also useful as diagnostics for the detection of hepatitis delta virus in tissue and fluid samples, as in blood banking, as well as in isolation and characterization of new viroids having ribozyme activity, using an RNA-specific hybridization method. Based on analysis of the two domain structure of the hepatitis delta virus, it is possible to construct a vector for expression of non-hepatitis delta virus proteins in mammalian cells.
Inventors
- 👤 Hugh D. Robertson
- 👤 Allan R. Goldberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 08:05
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/16; C12N9/22; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1131; C12N15/1132; C07; C07K; C07K14/00; C07K14/005; C12N5/00; C12N5/10; C12P; C12P21/00; C12P21/02; A; A61; A61K; A61K38/00; C07K2319/00; C12N2310/00; C12N2310/10; C12N2310/11; C12N2310/111; C12N2310/12; C12N2310/123; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/16011; C12N2740/16022; C12N2760/00; C12N2760/00011; C12N2760/10011; C12N2760/10111; C12N2760/10122
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
101 words
A method for cleaving a target RNA molecule comprising: mixing with the target RNA molecule a separate delta RNA fragment consisting of at least 18 consecutive nucleotides from the conserved region of the hepatitis delta virus, wherein the conserved region of the hepatitis delta RNA is selected from the group consisting of regions of hepatitis delta virus having ribozyme activity between residues 611 and 771 on the genomic strand and between residues 845 and 980 on the complementary anti-genomic strand, wherein the RNA fragment having ribozyme activity cleaves the target RNA molecule to form a 2',3' cyclic phosphate and 5' hydroxyl.
Claim 2
Independent Claim
101 words
A method for cleaving a target RNA molecule comprising: mixing with the target RNA molecule a separate delta RNA fragment consisting of at least 18 consecutive nucleotides from the conserved region of the hepatitis delta virus, wherein the conserved region of the hepatitis delta RNA is selected from the group consisting of regions of hepatitis delta virus having ribozyme activity between residues 611 and 771 on the genomic strand and between residues 845 and 980 on the complementary anti-genomic strand, wherein the RNA fragment having ribozyme activity cleaves the target RNA molecule to form a 2',3' cyclic phosphate and 5' hydroxyl.
Claim 3
Dependent Claim
25 words
The method of claim 1 further comprising labelling the delta RNA fragment having ribozyme activity prior to mixing the fragment with the target RNA molecule.
Claim 4
Dependent Claim
39 words
The method of claim 2 further comprising screening isotropic cells with the labelled delta RNA fragment and detecting RNA molecules which form secondary and tertiary structure with the delta RNA fragment and are cleaved by the delta RNA fragment.
Claim 5
Dependent Claim
25 words
The method of claim 1 wherein the target RNA molecule is the genome of a RNA virus or an mRNA encoded by an RNA virus.
Claim 6
Dependent Claim
19 words
The method of claim 4 wherein the RNA virus is selected from the group consisting of HIV-1 and HTLV-1.
Claim 7
Dependent Claim
26 words
The method of claim 1 further comprising inserting the delta RNA fragment into a retroviral vector prior to mixing the fragment with the target RNA molecule.
Claim 8
Dependent Claim
30 words
The method of claim 1 wherein the RNA fragment with ribozyme activity forms regions of secondary structure with the target RNA molecule between 10 and 20 base pairs in length.
Claim 9
Dependent Claim
46 words
The method of claim 1 wherein the RNA fragment is selected from the group consisting of regions of hepatitis delta virus between residues 611 and 771 on the genomic strand and regions of hepatitis delta virus between residues 816 and 980 on the complementary anti-genomic strand.
Claim 10
Dependent Claim
41 words
The method of claim 8 wherein the RNA molecule with ribozyme activity forms local tertiary structure with the target RNA molecule that is structurally equivalent to the tertiary structure formed between residues 703 to 735 of hepatitis delta virus genomic strand.
References Cited (Backward Citations)
US4795700A
Cited
US4888278A
Cited
WO1987003161A1
Cited
WO1988000478A1
Cited
WO1989005852A1
Cited
EP0389299A1
Cited
JPH02295883A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-07-05 | 1997-01-04 | 1997-07-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-07-05 | 2001-01-04 | 2001-07-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-07-05 | 2005-01-04 | 2005-07-06 | $7700.00 | Window Closed / Lapsed |